{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:13:09Z","timestamp":1789834389639,"version":"4.0.1"},"reference-count":18,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,9,22]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>An incidental histologic diagnosis of DLBCL was identified during temporary interruption of ibrutinib treatment in patients with CLL. In contrast to an aggressive clinical course typical of Richter transformation, these patients responded to reinitiation of ibrutinib alone.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020002454","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T15:43:00Z","timestamp":1600443780000},"page":"4508-4511","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":24,"title":["Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-3024","authenticated-orcid":false,"given":"Paul J.","family":"Hampel","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8266-8447","authenticated-orcid":false,"given":"Hua-Jay J.","family":"Cherng","sequence":"additional","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy G.","family":"Call","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Khanlari","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6918-3376","authenticated-orcid":false,"given":"Ellen D.","family":"McPhail","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8467-5464","authenticated-orcid":false,"given":"Roberto N.","family":"Miranda","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1942-851X","authenticated-orcid":false,"given":"Hussein A.","family":"Tawbi","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Leukemia and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3221-7314","authenticated-orcid":false,"given":"Sameer A.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"issue":"22","key":"2020091811384216000_B1","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1182\/blood.2019896688","article-title":"Clinically indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL","volume":"133","author":"Ahn","year":"2019","journal-title":"Blood"},{"issue":"12","key":"2020091811384216000_B2","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/bloodadvances.2018028761","article-title":"Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies","volume":"3","author":"Coutre","year":"2019","journal-title":"Blood Adv"},{"key":"2020091811384216000_B3","first-page":"204","article-title":"Disease flares during temporary interruption of ibrutinib therapy in patients with chronic lymphocytic leukemia","volume":"61","author":"Hampel","year":"2020","journal-title":"Leuk Lymphoma."},{"issue":"5","key":"2020091811384216000_B4","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","author":"Mato","year":"2017","journal-title":"Ann Oncol"},{"issue":"12","key":"2020091811384216000_B5","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients","volume":"101","author":"UK CLL Forum","year":"2016","journal-title":"Haematologica"},{"issue":"19","key":"2020091811384216000_B6","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","article-title":"Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL","volume":"129","author":"Barr","year":"2017","journal-title":"Blood"},{"issue":"25","key":"2020091811384216000_B7","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"2020091811384216000_B8"},{"issue":"1","key":"2020091811384216000_B9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2020091811384216000_B10","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1097\/PAS.0000000000001077","article-title":"PD-1 expression in chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) and large B-cell Richter transformation (DLBCL-RT): a characteristic feature of DLBCL-RT and potential surrogate marker for clonal relatedness","volume":"42","author":"He","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"2020091811384216000_B11","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"11","key":"2020091811384216000_B12","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1182\/blood-2013-11-516229","article-title":"How we treat Richter syndrome","volume":"123","author":"Parikh","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2020091811384216000_B13","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1002\/cncr.30596","article-title":"Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"2020091811384216000_B14","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","article-title":"Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia","volume":"1","author":"Maddocks","year":"2015","journal-title":"JAMA Oncol"},{"issue":"3","key":"2020091811384216000_B15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.3324\/haematol.2019.224121","article-title":"Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center","volume":"105","author":"Wang","year":"2020","journal-title":"Haematologica"},{"issue":"11","key":"2020091811384216000_B16","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1080\/10428194.2019.1602268","article-title":"Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice","volume":"60","author":"Hampel","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"15","key":"2020091811384216000_B17","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1182\/blood-2013-03-489518","article-title":"Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome","volume":"122","author":"Chigrinova","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2020091811384216000_B18","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.clml.2015.02.001","article-title":"Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemia","volume":"15","author":"Strati","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/18\/4508\/1758466\/advancesadv2020002454.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/18\/4508\/1758466\/advancesadv2020002454.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T15:43:18Z","timestamp":1600443798000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/18\/4508\/463770\/Incidental-Richter-transformation-in-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":18,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020,9,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020002454","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]}}}